TEAMThe strength of any organization is its people. Our independent Board of Directors is composed of some of the most active and well regarded individuals in healthcare; bringing a span of operational, clinical and financial insight.
CEOBrian Bell began his career as a technology and health care analyst for several mutual fund companies, including PIMCO Advisors ($180 billion in assets under management) and most recently with Seed Capital Partners, LLC, an early stage venture fund with backing from Softbank Corporation and JP Morgan Partners.
Bradley Fuhrman, MD
Founder & Chief Medical OfficerDr. Fuhrman trained in Pediatrics, Neonatology and Pediatric Cardiology at the University of Minnesota, and went on to be Board Certified in those specialties and in Pediatric Critical Care Medicine. He developed the first Pediatric ICU at U of MN in 1979 and then practiced that subspecialty for over 3 decades at the U of MN, Children’s Hospital of Pittsburgh, Children’s Hospital of Buffalo and El Paso Children’s.
Technical DirectorMr. DuFaux combines over 20 years of experience in product and process development with extensive experience in manufacturing development, engineering, customer relationships, and intellectual property. His unique combination of industry experience, including medical devices, electronics & controls, advanced materials, consumer products, and chemicals, provides Mr. DuFaux with an effective development perspective.
RegulatoryKathy Selover, Regulatory – formerly, the Vice President of Regulatory at SmartPill Corporation and Graphic Controls, Kathy brings over thirty successful 510(k) submissions to the team.
DirectorGene has been a First Wave Tech Director since January 2011. He served as Chairman (1989-1997) and CEO and President (1990-1997) of GranCare, Inc., which, under his management, grew from under $10 million in revenue to become one of the nation’s largest publicly traded long-term healthcare providers with revenues in excess of $1 billion.
DirectorDr. Clemow serves as President and Chief Executive Officer of Regentis Biomaterials, a private company developing an innovative material for cartilage repair. Previously he held the position of President and Chief Executive Officer in a number of companies that he helped found including Nexgen Spine.
ChairmanMr. Joel Kanter has served as President of Windy City, Inc., a privately held investment firm, since July 1986. From 1989 to November 1999, Mr. Kanter also served as the Chief Executive Officer of Walnut Financial Services, Inc., a publicly traded company (Nasdaq: WNUT).
Raymond Dean Hautamaki, MD
DirectorRaymond Dean Hautamaki MD is board certified internal medicine-pulmonary/ critical care physician practicing in Sarasota, Florida. He attended the University of Florida in Gainesville , Florida for undergraduate studies and medical school.
DirectorWayne Hellman is founder of Advanced Lighting Technologies (ADLT) and served as its CEO since the company’s inception in 1983 to 2014. Prior to this, he worked at General Electric for 16 years. Mr. Hellman grew ADLT from $900,000 in first year revenues to over $250 million.
DirectorCary Sucoff has over 30 years of securities industry experience. Mr. Sucoff currently owns and operates Equity Source Partners, LLC an advisory and consulting firm. He has participated in the financing of hundreds of public and private companies.
DirectorAn experienced financial executive, Dan Penberthy is responsible for sourcing deals and administration of the Company’s investments. He also oversees our financial operations. He earned his Bachelor of Science from St. Bonaventure University and his Master of Business Administration from the State University of New York at Buffalo.
Gene Bauer, MD
Eugene Bauer is immediate past co-founder, Chief Medical Officer and member of the board of directors of Dermira, Inc., a biotechnology company recently acquired by Eli Lilly and Company. Prior to founding Dermira, he served as a member of the board of directors of Peplin, Inc., where he also was its President and Chief Medical Officer, until Peplin’s acquisition by LEO Pharma in 2009.